Metastasis From Malignant Tumor of Soft Tissues
Conditions
Brief summary
In this study the investigators treat PM oligometastatic patients with SBRT. Our objective is to evaluate rate of local control of treated lesions in patients treated with Intensity Modulated Radiation Therapy (IMRT) using Volumetric Modulated Arc Therapy (VMAT) for lung metastases from STS.
Detailed description
The investigators started to treat PM oligometastatic patients with Stereotactic Body Radiotherapy. The investigators objective is to evaluate rate of local control of treated lesions in patients treated with Intensity Modulated Radiation Therapy (IMRT) using Volumetric Modulated Arc Therapy (VMAT) for lung metastases from soft-tissue sarcomas. Overall and disease free survival will be evaluated as secondary endpoints.
Interventions
RADIATIONLung metastasis from soft-tissue sarcoma
Tretament based on Intensity Modulated Radiation Therapy (IMRT) using Volumetric Modulated Arc Therapy (VMAT)
Sponsors
Istituto Clinico Humanitas
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes
Inclusion criteria
* Age 18 anni -85 years * PS according to ECOG 0-2 * Histopathologically confirmation of soft tissue sarcoma * Metastatic lung lesion less than 4 * Controlled primary tumor and other metastatic lesions * Metastatic lesion less than 5 such as the definition of oligometastatic patients * Written informed consent * Contraindication to surgical resection * Estimated survival ≥ 3 months * Absence of progressive disease longer than 6 months * No chemotherapy was given for at least 3 months after SBRT * Maximum diameter ≤ 5 cm
Exclusion criteria
* Prior thorax radiation therapy * Age \> 85 years * PS according to ECOG \>2 * Pregnant women * Maximum diameter ≥ 5.1 cm * Total volume of lung lesion greater than 1/3 of the whole pulmonary parenchima
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Local control of treated lesions | 12 months | Evaluation of proportion of patients free from progression from starting radiotherapy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival of treated patients | 4 years | Evaluation of proportion of patients alive |
| Disease free survival of treated patients | 4 years | Evaluation of proportion of patients alive and free from progression |
Countries
Italy
Outcome results
None listed